(February 21, 2014) Neurodyn Inc. commenced a Phase 1A clinical trial of its Alzheimer’s drug Memogain® in December 2013. In order to further support the Memogain Development Program, the company has assembled a advisory board of respected industry leaders to assist and guide the company as it plans the regulatory pathway for this promising Alzheimer’s prescription drug candidate. As a pro-drug of an already approved Alzheimer’s disease drug, with a much improved safety and efficacy profile, Memogain® may qualify for a more rapid and less costly path to market authorization by the US FDA.
Drs. Jim Olds, Chris Fibiger, Barry Greenberg and Mr. Jack Kay were named to the Memogain® Advisory Board. Each of them has made significant contributions in neuroscientific research, drug discovery, and pharmaceutical development worldwide.
Dr. Jim Olds earned his PhD in neurosciences and is currently the Director of the Krasnow Institute for Advanced Study, Professor of Neuroscience as well as Chair of the Department of Molecular Neuroscience at George Mason University, Virginia. Additionally, he has an academic faculty appointment at the Department of Anatomy and Cell Biology at the Uniformed Services University of the Health Sciences in Maryland. In August 2004, he was named editor-in-chief of the journal Biological Bulletin.
Dr. Chris Fibiger was once among the top 100 most cited scientists in neuroscience. He was formerly Vice President and Global Head of Neuroscience at Amgen, a multinational biopharmaceutical company, where he led worldwide neuroscience discovery efforts ranging from early exploratory research through clinical candidate selection. He is now the Chief Scientific Officer for Medgenesis Therapeutics Inc.
Dr. Barry Greenberg has been involved in Alzheimer’s disease research and drug discovery since 1985. He is now Director of Neuroscience Drug Discovery & Development at the University Health Network and co-directing the Toronto Dementia Research Alliance as Director of Strategy, a consortium involving academic research and the five memory clinics at hospitals affiliated with the University of Toronto to create a citywide dementia research center.
Mr. Jack Kay has worked in the pharmaceutical industry for over 45 years, and, since 1995 has been President and Chief Operating Officer of Apotex Inc., the largest Canadian-owned group of pharmaceutical companies.
“We are thankful to be able to benefit from the guidance and insights of these recognized experts,” says Kenneth Cawkell, Neurodyn’s CEO. “Together, they will bring many years of experience and perspective to our task of optimizing our development strategy for Memogain®and ensure its successful commercialization.”
For more information, please contact:
Neurodyn Life Science Inc.